Noticias y vídeos - FIBROGEN INC

Thinking about buying stock in Infobird, PubMatic, Hims & Hers Health, FibroGen, or Alpha Metallurgical Resources? PR Newswire NEW YORK, Feb. 27, 2024 NEW YORK , Feb. 27, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IFBD, PUBM, HIMS, FGEN, and AMR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. IFBD:...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN PR Newswire NEW YORK, July 17, 2023 NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether FibroGen and certain of its officers and/or...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN PR Newswire NEW YORK, July 12, 2023 NEW YORK , July 12, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether FibroGen and certain of its officers and/or...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN PR Newswire NEW YORK, July 3, 2023 NEW YORK , July 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether FibroGen and certain of its officers and/or...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. (“FibroGen” or “the Company”) (NASDAQ: FGEN ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. If you are a shareholder who suffered a loss, click here to participate . We also encourage you to...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. (“FibroGen” or “the Company”) (NASDAQ: FGEN ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. If you are a shareholder who suffered a loss, click here to participate . We also encourage you to...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), provides an update to KSF’s continued investigation into FibroGen, Inc. (NasdaqGS: FGEN). On April 6, 2021, the Company disclosed that cardiovascular safety data it had previously submitted for the Phase 3 program of its Roxadustat product “included post-hoc changes to the stratification factors.” Then, on July 15, 2021, the FDA’s Advisory Committee...

FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN PR Newswire NEW ORLEANS, Aug. 5, 2022 NEW ORLEANS , Aug. 5, 2022 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), provides an update to KSF's continued investigation into FibroGen, Inc. (NasdaqGS: FGEN). On April 6,...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), provides an update to KSF’s continued investigation into FibroGen, Inc. (NasdaqGS: FGEN). On April 6, 2021, the Company disclosed that cardiovascular safety data it had previously submitted for the Phase 3 program of its Roxadustat product “included post-hoc changes to the stratification factors.” Then, on July 15, 2021, the FDA’s Advisory Committee...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into FibroGen, Inc. (NasdaqGS: FGEN). On April 6, 2021, the Company disclosed that cardiovascular safety data it had previously submitted for the Phase 3 program of its roxadustat product “included post-hoc changes to the stratification factors.” As a result of these changes, the complaint alleges, the Company was...

FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGEN PR Newswire NEW ORLEANS, May 13, 2022 NEW ORLEANS , May 13, 2022 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into FibroGen, Inc. (NasdaqGS: FGEN). On April 6, 2021 , the Company...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into FibroGen, Inc. (NasdaqGS: FGEN). On April 6, 2021, the Company disclosed that cardiovascular safety data it had previously submitted for the Phase 3 program of its roxadustat product “included post-hoc changes to the stratification factors.” As a result of these changes, the complaint alleges, the Company was...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into FibroGen, Inc. (NasdaqGS: FGEN). On April 6, 2021, the Company disclosed that cardiovascular safety data it had previously submitted for the Phase 3 program of its roxadustat product “included post-hoc changes to the stratification factors.” As a result of these changes, the complaint alleges, the Company was...

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fibrogen, Inc. (NASDAQ: FGEN) on behalf of long-term stockholders following a class action complaint that was filed against Fibrogen on April 12, 2021. Our investigation concerns whether the board of directors of Fibrogen have breached their fiduciary duties to the company. The complaint alleges that defendants failed to disclose to investors: (i) that the Company’s prior...

Thinking about buying stock in RenovoRx, Roblox, Fubotv, Unity Biotechnology, or FibroGen? PR Newswire NEW YORK, Nov. 10, 2021 NEW YORK , Nov. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RNXT, RBLX, FUBO, UBX, and FGEN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. RNXT:...

FIBROGEN 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against FibroGen, Inc. - FGEN PR Newswire NEW ORLEANS, June 10, 2021 NEW ORLEANS , June 10, 2021 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana , Charles C. Foti, Jr. , remind investors that they have only until June 11, 2021 to file lead plaintiff...

The Law Offices of Frank R. Cruz reminds investors of the upcoming June 11, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired FibroGen Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN ) securities between November 8, 2019 and April 6, 2021 , inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. FibroGen is a biopharmaceutical company that develops...

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until June 11, 2021 to file lead plaintiff applications in securities class action lawsuits against FibroGen, Inc. (NasdaqGS: FGEN), if they purchased the Company’s securities and/or sold put options between October 18, 2017 and April 6, 2021, inclusive (the “Class Period”). These actions are pending in the United States District Court for the...

Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against FibroGen, Inc. PR Newswire RADNOR, Pa., June 7, 2021 RADNOR, Pa. , June 7, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put...

Class Action Lawsuit Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. PR Newswire RADNOR, Pa., June 1, 2021 RADNOR, Pa. , June 1, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put...